1332327-18-0

Basic information

• Product Name: 1-[4-(4-methyl-piperazine-1-carbonyl)-phenyl]-3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-urea
• Synonyms: 1-[4-(4-methyl-piperazine-1-carbonyl)-phenyl]-3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-urea
• CAS NO: 1332327-18-0
• Molecular Weight: 464.372
• Mol File: 1332327-18-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-[4-(4-methyl-piperazine-1-carbonyl)-phenyl]-3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[4-(4-methyl-piperazine-1-carbonyl)-phenyl]-3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-urea(1332327-18-0)
• EPA Substance Registry System: 1-[4-(4-methyl-piperazine-1-carbonyl)-phenyl]-3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-urea(1332327-18-0)

Safety Data

• Hazardous Substances Data: 1332327-18-0(Hazardous Substances Data)

Upstream product

• 367-24-8 4-bromo-2-fluoroaniline 
• 55121-99-8 (4-aminophenyl)(4-methylpiperazin-1-yl)methanone 
• 62-23-7 4-nitro-benzoic acid 
• 21091-98-5 (4-methylpiperazin-1-yl)(4-nitrophenyl)methanone 
• 109-01-3 1-methyl-piperazine 

Downstream Products

• 1197168-44-7 C₂₆H₃₀N₈O₄ 
• 1374203-75-4 4-(3-{4-[8-(3-hydroxy-phenyl)-4-morpholin-4-yl-quinazolin-2-yl]-phenyl}-ureido)-N,N-dimethyl-benzamide 
• 1374203-74-3 1-[4(6-fluoro-4-morpholin-4-yl-7-pyridin-3-yl-quinazolin-2-yl)-phenyl]-3-[4-(4-methyl-piperazine-1-carbonyl)-phenyl]-urea 

Relevant articles and documents

SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES

The present application provides novel substituted quinazoline and pyrido- pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.